(secondQuint)A Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia.

 The drug being tested in this study is called TAK-041.

 TAK-041 is being tested to treat people who have stable schizophrenia.

 This study will look whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved in people who take TAK-041 in addition to standard care.

 The study will enroll approximately 32 patients.

 Participants will be randomly assigned (by chance, like flipping a coin) in 1:1 ratio to one of the two treatment sequences -which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need) to receive either TAK-041 40 mg or Placebo first and then will be crossed over to receive the opposite Intervention All participants will be asked to take oral suspension on Day 1 of each period.

 There will be a wash-out period of 35 days between the dosing days in Period 1 and 2.

 This single-center trial will be conducted in the United Kingdom.

 The overall time to participate in this study is approximately 126 to 154 days.

 Participants will make a multiple visits to the clinic plus a final visit 77 days after receiving their last dose of drug for a follow-up assessment.

.

 A Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia@highlight

The purpose of the study is to determine whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved by add-on TAK-041 administration to antipsychotics in participants with stable schizophrenia.

